CRVO CervoMed Inc

$CRVO quote from Alam in today’s fireside chat: “We believe with everything that we have now, we are incredibly well-positioned for a strategic partner. When you are going into licensing, the clinical trial risk is one part of it and the clinical catalyst, but they want CMC, non-clinical, across the board. Everyone has a veto power. Today, here and now, I think we have everything, including on the non-clinical. We reported in June that we had repeated one of the long-term dog toxicology studies. Our safety margin is now 30-fold, which has been a question around P38 inhibitors. When you are at 30-fold, there is no question. That is our primary focus. Financing could be a complement to that, but our primary focus right now is that we think we have a phase III-ready drug in a large indication with all the boxes checked. This will be of interest to a strategic partner.“

$CRVO Wishing folks luck Monday morning…I’ll look to enter after in pre market. Sunday is Phase 2a biomarker data, not Phase 2b or a buyout. More importantly, Series C ($3.14) and B ($3.32) warrants sit right overhead. Structured funds box and short pops against those strikes, then exercise to cover. That kind of float expansion caps runs long before they get exciting. PIPE desks hedge and short into catalyst runs, covering with warrant exercises. Sabby will run the usual game here and they have been doing it for a long time. Regardless, I’m excited for the science and hope folks make money….👍

$CRVO good luck to us all tomorrow! In August they reported the first 8 as “very encouraging” 🤞

$CRVO If the data is good, there will be a short squeeze on Monday. Every time the data is convincing, there's a squeeze of at least 200%. That would currently be around $9.

$CRVO phase 3 is going to happen. So the two routes are 1) partnership. 2) financing. A phase three trial for this kind of indication would normally warrant a 250-400m valuation. Current valuation is 40m. If a partner is secured even on poor terms valuation would be 2-3 times minimum what it is today. On good terms 8 x or more. If they had to finance and dilute massively, say even to a crazy 80% but therefore kept all the future value of the drug within the company, then it should be worth more than 300m. In that scenario the shares are still 60 per cent undervalued. The company states clearly option 1) is where they are aiming and have all the boxes ticked for this to succeed. The downside here seems pretty small. What am I missing?

$CRVO even with the shorts in room with us, its nice to see how the stock easily has theese bounce backs

$CRVO On Sunday, 11 October 2026, CervoMed will present initial Phase 2a clinical trial results for neflamapimod in nfvPPA, a form of frontotemporal dementia.

$CRVO The tipping point is here. We're heading higher for good now. Sunny skies are ahead. Hope everyone has already gotten theor shares.

$CRVO To Claude: What is the probability or percentage of Cervomed's latest data drop being positive at this Sunday's conference presentation regarding the trial results that they plan to divulge? The company describes the results as positive or encouraging: about 85-90%. Companies rarely headline a late-breaking slot with bad news, and management called the trends in the first eight participants “highly encouraging.” The presentation was also expanded from those eight patients to at least 22, which suggests the early signal held up well enough to show.

$CRVO Looks like a little accumulation is starting ahead of data releases next month and I suspect partnership news or minimally updates by November. Volume still way too low for shorts to exit. They’re largely in the green but bleeding profits daily with borrow fees.

$CRVO 4 hours until the presentation. I'm keeping my fingers crossed for all of us. Don't forget, Cervomed is a super low floater. And no matter how things turn out today, I'm super positive for the company, because the guy from Vertex pharmaceuticals is involved and he's the one who made Vertex big. He knows his stuff and has been working on it for a very long time.

$CRVO As i wrote, price target on monday $9. Lets see and hope. I think this is really realistic, what do you think?

$CRVO The global Lewy body Dementia treatment market is projected to reach $8.45 billion by 2033.

$CRVO finnaly trend reversal in chart, with this market cap and amount of good news that we got and news to look forward to , the stock price wont stay like this for long

$CRVO Low volume . See if shabby starts to cover next few weeks. Took small lotto for readout.

$CRVO I’ll take my 20%, second swing here and definitely on watch to ride it again. Took my profits. 👍

$CRVO John Alam and Joshua Boger possess a significant advantage in soliciting a partnership: they do not need to rely on cold outreach. The drug they are developing, neflamapimod, was originally discovered at Vertex Pharmaceuticals during Boger’s tenure as CEO. Because of this, the asset's history and their leadership are already well-known within elite biopharma circles. Socializing this opportunity among their extensive network of industry leaders is not only possible—it is the core channel through which they should initiate a deal. To execute this outreach effectively, they should deploy a two-pronged strategy combining targeted executive socialization with a structured corporate development process.

$CRVO getting exciting with the news yesterday. We have data readout October 11th then we need a partnership or finances. Should be a fun couple of months

$CRVO My thoughts on data in abstract, directionally good but not convincing. As an investment I didn't sign up for this drug in ftd I signed up for LBD - after seeing this biomarker data it's harder to dismiss but still lets be clear. GFAP is meaningless here. Patient have the same gfap going into the study as healthy controls. So what does this even mean. NFL is better, this could be noise or the beginnings of lowering of NFL keeps rising and the disease progresses. NFL is noisy and there are 8 patients so take it with a grain. I lost two immediate family members to this disease, so it's very personal.

$CRVO CRVO Conference Session Today Sunday, October 11, 2026 Part of the ISFTD 2026 conference in Philadelphia 8:30 – 10:30 AM EDT Presentation Topic: Preliminary biomarker results from the Phase 2a trial of neflamapimod for the treatment of a type of dementia known as nfvPPA.